Oct 2026· Frontiers in Pharmacology· Vol 17· 0 citations· 65 references
Medicine
TL;DR
Current evidence supports CLDN18.2 as a candidate biomarker for biomarker-enriched investigation, not as an established therapeutic target in CMA, and proposes a framework centered on lineage reprogramming, antigen enrichment, assay standardization, and therapeutic translation.
Abstract
Colorectal mucinous adenocarcinoma (CMA) is a histologically and molecularly distinct subtype of colorectal cancer (CRC), marked by abundant extracellular mucin, a predilection for the proximal colon, and frequent overlap with deficient mismatch repair/high microsatellite instability (dMMR/MSI-H), BRAF V600E mutation, CpG island methylator phenotype-high (CIMP-high) status, and serrated pathway biology. Although immune checkpoint inhibitors and molecularly targeted therapies have expanded treatment options for selected patients with advanced CRC, treatment strategies tailored to the histologic phenotype, lineage programs, and microenvironmental architecture of CMA remain limited. CLDN18.2, the gastric isoform encoded by CLDN18, is now a clinically validated therapeutic target in gastric and gastroesophageal junction (GEJ) adenocarcinomas. Recent pathology-based studies suggest that CLDN18.2 expression is uncommon in unselected conventional colorectal adenocarcinoma but enriched in CMA, mucin-rich CRC, and tumors with gastric-type or foregut-like differentiation, particularly those arising in the proximal colon or harboring dMMR/MSI-H status or BRAF V600E mutation. This pattern suggests that CLDN18.2 in CMA is unlikely to be a classic oncogenic driver; instead, it is better viewed as a therapeutically accessible, lineage-associated membrane antigen. This review summarizes the biological rationale, expression data, companion diagnostic issues, therapeutic platforms, and translational barriers relevant to CLDN18.2 in CMA. We propose a framework centered on lineage reprogramming, antigen enrichment, assay standardization, and therapeutic translation. Current evidence supports CLDN18.2 as a candidate biomarker for biomarker-enriched investigation, not as an established therapeutic target in CMA. Future work should prioritize CMA-specific preclinical models, standardized membranous immunohistochemistry (IHC) scoring, and prospective trials that integrate CLDN18.2 expression with molecular subtype and tumor microenvironmental features.
While the immunohistochemical panel developed is of insufficient diagnostic accuracy to distinguish MOC from GA, consideration should be given to include MOC in clinical basket trials targeting ERBB2 and Claudin 18.2.
Shuai Wang, A. de Boeck, E. Kang et al.· International Journal of Gyn...· 0 citations
Background: Breast mucinous cystadenocarcinoma (BMCA) is an exceptionally rare malignancy that may resemble mucinous neoplasms of the pancreas, ovary, lung, and colorectum. Claudin 18 (CLDN18), particularly its gastric-associated isoform CLDN18.2, is an emerging therapeutic target; however, CLDN18 immunoreactivity has...
Shih-En Lin, Shih-Jheng Liou, Wan-Ching Chen et al.· Journal of the Chinese Medic...· 0 citations
PURPOSE
Gastrointestinal neuroendocrine carcinomas (GI-NECs) are aggressive tumors with marked site-specific heterogeneity, yet molecular markers for colorectal origin are lacking. This study characterized genomic and protein expression profiles to identify origin-specific biomarkers.
METHODS
Nineteen GI-NECs (7 esop...
Jin-Ping Zhang, Weili Long, Jing Ma et al.· Pathology, Research and Prac...· 0 citations
Gastroesophageal adenocarcinoma (GEA) remains a major cause of cancer morbidity and mortality, with substantial geographic variation and marked inter- and intratumoral heterogeneity. The implementation of predictive biomarkers, including human epidermal growth factor 2 (HER2) overexpression/amplification, programmed de...
M. Alsina, E. Terán, T. F. Kanonnikoff· ESMO gastrointestinal oncolo...· 0 citations
Microsatellite-stable (MSS) colorectal cancer (CRC) is a molecularly complex and clinically challenging disease subtype, lacking effective targeted therapies. Leveraging multiomic data from ∼2,000 tumor samples (including 316MSS CRCs not previously profiled) representing ∼4,500 molecular profiles and 195,246 single cel...
A. Sadanandam, A. O'Farrell, I. Miller et al.· Cancer Cell· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.